Voss Capital, LLC Uni Qure N.V. Transaction History

Voss Capital, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$13.15 - $20.45 $1.71 Million - $2.66 Million	130,000 New	130,000 $2.42 Million
Q1 2022 May 13, 2022	BUY	$14.54 - $21.5 $1.02 Million - $1.51 Million	70,000 New	70,000 $1.27 Million
Q3 2021 Nov 16, 2021	SELL	$26.01 - $38.22 $1.05 Million - $1.54 Million	-40,403 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$29.97 - $37.17 $1.49 Million - $1.84 Million	-49,597 Reduced 55.11%	40,403 $1.25 Million
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $731,000 - $1.05 Million	25,000 Added 38.46%	90,000 $3.03 Million
Q4 2020 Feb 12, 2021	SELL	$35.35 - $50.67 $1.3 Million - $1.86 Million	-36,766 Reduced 36.13%	65,000 $2.35 Million
Q3 2020 Nov 12, 2020	BUY	$35.98 - $47.66 $1.14 Million - $1.51 Million	31,766 Added 45.38%	101,766 $3.75 Million
Q2 2020 Aug 13, 2020	SELL	$45.06 - $67.74 $2.59 Million - $3.9 Million	-57,500 Reduced 45.1%	70,000 $3.15 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $2.12 Million - $3.92 Million	-52,997 Reduced 29.36%	127,500 $3.26 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $6.7 Million - $13.5 Million	180,497 New	180,497 $12.9 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Voss Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Voss Capital, LLC with notifications on news.